Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Enfortumab vedotin: targeting bladder cancer

The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here, Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses data for the antibody-drug conjugate enfortumab vedotin, which targets Nectin-4 (EV-101; NCT02091999).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.